Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression
News provided by
Share this article
Share this article
TOKYO, April 23, 2021 /PRNewswire/ -- Jolly Good Inc. ("Jolly Good") and Teijin Pharma Ltd. ("Teijin Pharma") have signed a business partnership agreement to develop VR digital therapeutics ("VR DTx") for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for depression, aiming for PMDA regulatory approval.
Background of this agreement
Jolly Good and Teijin Pharma Form a Partnership to Develop VR Digital Therapeutics for Depression
This all started when Jolly Good won "Home Healthcare Award" in a program held by Teijin in Dec., 2020. Focusing of Jolly Good's development of Cognitive Behavioral Therapy VR ("CBT VR") for psychiatric disorders, this partnership will leverage Jolly Good's VR technology and Teijin Pharma's expertise in knowledge and strategic skills. They have agreed that they can support healthcare workers as well as improving the quality of life of patients.